Literature DB >> 11407649

Neuroendocrine effects of subcutaneous sumatriptan in patients with migraine.

I Rainero1, W Valfrè, L Savi, S Gentile, L Pinessi, L Gianotti, E Arvat, E Ghigo, P Del Rizzo, P Calvelli, P Limone.   

Abstract

We evaluated the sensitivity of 5-HT1D receptors in patients with migraine using sumatriptan as a pharmacological probe. The drug inhibits the release of ACTH, cortisol and prolactin and this effect may be used to explore the function of serotoninergic systems in vivo. We administered sumatriptan (6 mg sc) and placebo to 15 migraineurs, during the headache-free period, and to 10 healthy controls. Blood samples were collected -15, 0, 15, 30, 45, 60 and 90 min after injections. Sumatriptan induced a significant (p<0.01) decrease of ACTH, cortisol and prolactin concentrations both in patients with migraine and in controls. The neuroendocrine response was not significantly different in the two groups. Our results suggest that 5-HT1D receptor sensitivity is not altered in migraine.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11407649     DOI: 10.1007/BF03343866

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  26 in total

1.  Abnormal 5-HT1D receptor function in major depression: a neuropharmacological challenge study using sumatriptan.

Authors:  A J Cleare; R M Murray; R A Sherwood; V O'Keane
Journal:  Psychol Med       Date:  1998-03       Impact factor: 7.723

2.  Use of sumatriptan in Denmark in 1994-5: an epidemiological analysis of nationwide prescription data.

Authors:  D Gaist; M Andersen; A L Aarup; J Hallas; L F Gram
Journal:  Br J Clin Pharmacol       Date:  1997-04       Impact factor: 4.335

3.  Neuroendocrine effects of sumatriptan.

Authors:  J R Herdman; N J Delva; R E Hockney; G M Campling; P J Cowen
Journal:  Psychopharmacology (Berl)       Date:  1994-01       Impact factor: 4.530

4.  5-HT1A receptor hypersensitivity in migraine is suggested by the m-chlorophenylpiperazine test.

Authors:  M Leone; A Attanasio; D Croci; A Ferraris; D D'Amico; L Grazzi; A Nespolo; G Bussone
Journal:  Neuroreport       Date:  1998-08-03       Impact factor: 1.837

5.  Induction of migrainelike headaches by the serotonin agonist m-chlorophenylpiperazine.

Authors:  T D Brewerton; D L Murphy; E A Mueller; D C Jimerson
Journal:  Clin Pharmacol Ther       Date:  1988-06       Impact factor: 6.875

6.  Pharmacokinetic and pharmacodynamic profile of oral and intravenous meta-chlorophenylpiperazine in healthy volunteers.

Authors:  H J Gijsman; J M Van Gerven; M C Tieleman; R C Schoemaker; M S Pieters; M D Ferrari; A F Cohen; G M Van Kempen
Journal:  J Clin Psychopharmacol       Date:  1998-08       Impact factor: 3.153

7.  Migraine to the year 2000.

Authors:  M Sandler
Journal:  Cephalalgia       Date:  1995       Impact factor: 6.292

8.  The neuroendocrine challenge paradigm in headache research.

Authors:  M L Gordon; R B Lipton; S L Brown; H M van Praag
Journal:  Cephalalgia       Date:  1995       Impact factor: 6.292

Review 9.  Migraine and cluster headache--their management with sumatriptan: a critical review of the current clinical experience.

Authors:  M Wilkinson; V Pfaffenrath; J Schoenen; H C Diener; T J Steiner
Journal:  Cephalalgia       Date:  1995-10       Impact factor: 6.292

10.  Role of the serotonin receptor subtype 5-HT1D on basal and stimulated growth hormone secretion.

Authors:  A Mota; A Bento; A Peñalva; M Pombo; C Dieguez
Journal:  J Clin Endocrinol Metab       Date:  1995-06       Impact factor: 5.958

View more
  3 in total

Review 1.  Childhood abuse and migraine: epidemiology, sex differences, and potential mechanisms.

Authors:  Gretchen E Tietjen; B Lee Peterlin
Journal:  Headache       Date:  2011-06       Impact factor: 5.887

2.  Evidence for hyperprolactinemia in migraineurs: a systematic review and meta-analysis.

Authors:  Ali Noori-Zadeh; Morvarid Karamkhani; Ali Seidkhani-Nahal; Afra Khosravi; Shahram Darabi
Journal:  Neurol Sci       Date:  2019-08-23       Impact factor: 3.307

3.  [Altered function of the hypothalamic-pituitary-adrenal axis in patients with acute, chronic and episodic pain].

Authors:  M Strittmatter; O Bianchi; D Ostertag; M Grauer; C Paulus; C Fischer; S Meyer
Journal:  Schmerz       Date:  2005-04       Impact factor: 1.107

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.